These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 16741022

  • 1. Reversal of elevated cardiac expression of TGFbeta1 and endothelin-1 in OLETF diabetic rats by long-acting calcium antagonist.
    Jesmin S, Zaedi S, Maeda S, Mowa CN, Sakuma I, Miyauchi T.
    Exp Biol Med (Maywood); 2006 Jun; 231(6):907-12. PubMed ID: 16741022
    [Abstract] [Full Text] [Related]

  • 2. The calcium channel antagonist benidipine reduces plasma and cardiac endothelin-1 levels in type II diabetic rat model.
    Jesmin S, Sakuma I, Hattori Y, Kitabatake A, Miyauchi T.
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S49-53. PubMed ID: 15838356
    [Abstract] [Full Text] [Related]

  • 3. Effects of the AT(1) receptor blocker losartan and the calcium channel blocker benidipine on the accumulation of lipids in the kidney of a rat model of metabolic syndrome.
    Ishizaka N, Hongo M, Matsuzaki G, Furuta K, Saito K, Sakurai R, Sakamoto A, Koike K, Nagai R.
    Hypertens Res; 2010 Mar; 33(3):263-8. PubMed ID: 20057486
    [Abstract] [Full Text] [Related]

  • 4. Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a Type II diabetic rat model.
    Jesmin S, Sakuma I, Hattori Y, Fujii S, Kitabatake A.
    Diabetologia; 2002 Mar; 45(3):402-15. PubMed ID: 11914746
    [Abstract] [Full Text] [Related]

  • 5. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
    Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, Takeuchi H, Mizushige K, Kohno M.
    J Am Coll Cardiol; 2004 Aug 18; 44(4):904-13. PubMed ID: 15312879
    [Abstract] [Full Text] [Related]

  • 6. Vascular proliferation and transforming growth factor-beta expression in pre- and early stage of diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats.
    Hosomi N, Noma T, Ohyama H, Takahashi T, Kohno M.
    Atherosclerosis; 2002 May 18; 162(1):69-76. PubMed ID: 11947899
    [Abstract] [Full Text] [Related]

  • 7. Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats.
    Koike T, Tomoda F, Kinuno H, Inoue H, Takata M.
    Acta Physiol Scand; 2005 May 18; 184(1):73-81. PubMed ID: 15847646
    [Abstract] [Full Text] [Related]

  • 8. Effect of timely insulin administration on pancreatic B-cells of Otsuka-Long-Evans-Tokushima-Fatty (OLETF) strain rats. An animal model of non-insulin dependent diabetes mellitus (NIDDM).
    Ishida K, Mizuno A, Sano T, Noma Y, Shima K.
    Horm Metab Res; 1995 Sep 18; 27(9):398-402. PubMed ID: 8557237
    [Abstract] [Full Text] [Related]

  • 9. High salt intake elevated blood pressure but not changed circadian blood pressure rhythm in Otsuka Long-Evans Tokushima Fatty (OLETF) rat.
    Matsumoto M, Tsujino T, Naito Y, Sakoda T, Ohyanagi M, Nonaka H, Masuyama T.
    Clin Exp Hypertens; 2009 May 18; 31(3):271-80. PubMed ID: 19387903
    [Abstract] [Full Text] [Related]

  • 10. Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima fatty rat: a model of human type 2 diabetes mellitus.
    Yamabe N, Yokozawa T.
    J Pharm Pharmacol; 2006 Apr 18; 58(4):535-45. PubMed ID: 16597372
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS.
    Diabetes Metab Res Rev; 2003 Apr 18; 19(6):487-93. PubMed ID: 14648808
    [Abstract] [Full Text] [Related]

  • 13. Downregulation of the skeletal muscle pyruvate dehydrogenase complex in the Otsuka Long-Evans Tokushima Fatty rat both before and after the onset of diabetes mellitus.
    Bajotto G, Murakami T, Nagasaki M, Tamura T, Tamura N, Harris RA, Shimomura Y, Sato Y.
    Life Sci; 2004 Sep 10; 75(17):2117-30. PubMed ID: 15312755
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Otsuka Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy.
    Matsuura T, Yamagishi S, Kodama Y, Shibata R, Ueda S, Narama I.
    Int J Tissue React; 2005 Sep 10; 27(2):59-62. PubMed ID: 16035649
    [Abstract] [Full Text] [Related]

  • 16. Adrenocortical insufficiency in Otsuka Long-Evans Tokushima Fatty rats, a type 2 diabetes mellitus model.
    Noguchi S, Ohno Y, Aoki N.
    Metabolism; 2007 Oct 10; 56(10):1326-33. PubMed ID: 17884440
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Biochemical and morphological changes during development of sugar cataract in Otsuka Long-Evans Tokushima fatty (OLETF) rat.
    Kubo E, Maekawa K, Tanimoto T, Fujisawa S, Akagi Y.
    Exp Eye Res; 2001 Sep 10; 73(3):375-81. PubMed ID: 11520112
    [Abstract] [Full Text] [Related]

  • 19. [Effects of Liuweidihuang pills on plasma adiponectin level in OLETF rats].
    Qian Y, Xue YM, Li J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan 10; 28(1):34-6. PubMed ID: 18227021
    [Abstract] [Full Text] [Related]

  • 20. Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome.
    Matsuzaki G, Ishizaka N, Furuta K, Hongo M, Saito K, Sakurai R, Koike K, Nagai R.
    Eur J Pharmacol; 2008 Jun 10; 587(1-3):237-42. PubMed ID: 18457832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.